Coeptis Therapeutics gets Nasdaq extension to Jan 15, 2025 to regain $1 bid price compliance

Z Squared Inc.

Nasdaq Hearings Panel granted continued listing through Jan 15, 2025, subject to compliance with Minimum Bid Price Requirement.
Company plans to implement a reverse stock split to regain compliance.
Original non-compliance notice received Jan 29, 2024; previous compliance period ended July 29, 2024.
CEO Dave Mehalick expressed optimism about regaining and maintaining Nasdaq listing.
Extension follows a hearing on Sep 12, 2024; company had appealed earlier delisting determination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.